High Complement Levels in Astrocyte-Derived Exosomes of Alzheimer Disease

Edward J. Goetzl, MD, Janice B. Schwartz, MD, Erin L. Abner, PhD, Gregory A. Jicha, MD, and Dimitrios Kapogiannis, MD

Objective: Astrocytes fulfill neuronal trophic roles normally, but are transformed in Alzheimer disease (AD) into A1-type reactive astrocytes that may destroy neurons through unknown mechanisms.

Methods: To investigate astrocyte inflammatory mechanisms, astrocyte-derived exosomes (ADEs) were isolated immunochemically from plasma samples of AD patients and matched controls for enzyme-linked immunosorbent assay quantification of complement proteins.

Results: ADE levels of C1q, C4b, C3d, factor B, factor D, Bb, C3b, and C5b-C9 terminal complement complex, but not mannose-binding lectin, normalized by the CD81 exosome marker were significantly higher for AD patients (n = 28) than age- and gender-matched controls (all p < 0.0001). ADE normalized levels of interleukin (IL)-6, tumor necrosis factor-α, and IL-1β were significantly higher for AD patients than controls, but there was greater overlap between the two groups than for complement proteins. Mean ADE levels of complement proteins for AD patients in a longitudinal study were significantly higher (n = 16, p < 0.0001) at the AD2 stage of moderate dementia than at the AD1 preclinical stage 5 to 12 years earlier, which were the same as for controls. ADE levels of complement regulatory proteins CD59, CD46, decay-accelerating factor (DAF), and complement receptor type 1, but not factor I, were significantly lower for AD patients than controls (p < 0.0001 for CD59 and DAF), were diminished by the AD1 stage, and were further decreased at the AD2 stage.

Interpretation: ADE complement effector proteins in AD are produced by dysregulated systems, attain higher levels than in controls, and may potentially damage neurons in the late inflammatory phase of AD.

Ann Neurol 2018;00:000–000

Astrocytes are abundant glial cells in the human central nervous system (CNS) that normally have a major neuronal trophic role through diverse homeostatic maintenance activities. Neuronal supportive functions of astrocytes include promotion of development, nutrition, survival, dendrite outgrowth, and synapse formation. Most inflammatory, neurodegenerative, and ischemic diseases of the CNS elicit a highly coordinated multicellular response that encompasses an increase in the total number of astrocytes and their differentiation into reactive astrocytes of inflammatory type A1 and/or ischemia-related type A2. Activated microglia are critical inducers of A1 inflammatory–neurotoxic astrocytes through NFκB-dependent pathways and a range of cytokines, but a greater understanding of mechanisms and specific mediators is still emerging. A2-type reactive astrocytes upregulate expression of neuronal protective functions and factors. In contrast, A1-type reactive astrocytes lose neuronal trophic potential and instead increase expression of proinflammatory pathways as well as toxic activities that damage synapses and destroy neurons. It is currently unclear which of the neuronal toxic mediators generated and secreted by A1-type astrocytes are pathogenically critical in human neurodegenerative diseases.

Findings in postmortem brain tissues of patients with neurodegenerative and neuroinflammatory diseases have begun to delineate specific components of type A1 astrocyte-mediated neuronal toxicity. Approximately 60% of type A1 (glial fibrillary acidic protein [GFAP]-

© 2018 American Neurological Association
positive) astrocytes in the prefrontal cortex of patients with Alzheimer disease (AD) express an abnormally high level of complement component 3 (C3), which is characteristically upregulated in induced A1-type astrocytes and has potential neuronal cytotoxic activity. The absence of C3 from type A2 (S100A10-positive) astrocytes in the same regions of brain tissues of patients with AD confirms the likely absence of complement-mediated neuronal cytotoxic activity of A2 astrocytes. Evidence of the possible pathogenic involvement of complement systems in AD has been presented, but it was not clear that astrocytes are the principal source of the complement mediators. Furthermore, in some animal models of AD, reactive astrocytes and complement have been found to protect neurons from the proteinopathic factors in AD.

Enriched populations of astrocyte-derived exosomes (ADEs) obtained from human plasma by sequential precipitation and immunochemical absorption contain much higher levels of the astrocyte biomarkers glutamine synthetase and GFAP than plasma neuron-derived exosomes (NDEs). In contrast, NDEs have much higher levels than ADEs of the neuronal markers neurofilament light chain and neuron-specific enolase. One pathogenic role for astrocytes in AD was suggested initially by our finding of higher levels of β-site amyloid precursor protein-claving enzyme 1 and soluble amyloid precursor protein β of the Aβ42 peptide-generating system in ADEs than NDEs and in ADEs of patients with AD than in those of matched controls.

Our current findings support possible pathogenic roles of type A1 astrocytes in AD through inflammatory complement proteins of both the classical and alternative systems in ADEs, which are elevated in patients with AD compared to those of matched controls. Diminished ADE levels of several complement regulatory proteins early in preclinical AD suggest that loss of normal inhibition of the classical and alternative complement pathways may be one primary cause of complement-mediated neuroinflammation in AD. These results also indicate that existing complement-directed therapies may benefit some patients with AD who have high levels of complement-mediated neuroinflammation.

### Subjects and Methods

**Experimental Design and Patient Evaluation**

For cross-sectional studies, we retrospectively identified 28 patients with early AD (mild cognitive impairment [MCI] or mild dementia) who had been evaluated extensively in the Clinical Research Unit of the U.S. National Institute on Aging (NIA; Baltimore, MD) and 28 age- and gender-matched cognitively normal controls who had donated blood at the Jewish Home of San Francisco (JHFS) in the same time period as the patients (Table 1). For longitudinal studies, we selected 16 patients at the University of Kentucky, Lexington (UKY) AD Center with moderate AD who had provided blood twice: first when cognitively intact (AD1, Table 2) and again 5 to 12 years later after diagnosis of dementia (AD2, Table 2). Sixteen cognitively normal controls, who were age- and gender-matched with the AD1 group, were found at JHFS based on their plasma samples having been obtained in the same time period. One investigator (E.J.G.) supervised identification and storage of all plasma samples by the same methods and processed all plasma samples together by the same procedures. Plasma samples from patients in the longitudinal studies were analyzed without knowledge of the clinical data.

Patients with AD and controls had mental status testing at the time of each blood sampling. Mini-Mental State Examination and the AD Assessment Scale–Cognitive Subscale were conducted as described. Cross-sectional study patients from the NIA had amnestic MCI or mild dementia with high probability of AD and a Clinical Dementia Rating global score of 0.5 or 1.0 according to the NIA–Alzheimer’s Association and International Working Group-2 criteria. All cross-sectional patients with AD had abnormal cerebrospinal fluid (CSF) levels of amyloid β-peptide (Aβ) 1–42 and P-T181-tau that supported their diagnosis. AD1/AD2 patients from UKY had probable AD and mild-to-moderate dementia at the AD2 stage by National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders

### Table 1. Characteristics of AD Patients and Control Subjects: Cross-Sectional Sets

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total No.</th>
<th>M/F</th>
<th>Age, Mean ± SEM</th>
<th>MMSE, Mean ± SEM</th>
<th>ADAS-cog, Mean ± SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>28</td>
<td>12/16</td>
<td>73.2 ± 1.47</td>
<td>29.7 ± 0.13</td>
<td>3.32 ± 0.31</td>
</tr>
<tr>
<td>AD</td>
<td>28</td>
<td>12/16</td>
<td>73.1 ± 1.44</td>
<td>25.6 ± 0.83*</td>
<td>13.7 ± 1.31*</td>
</tr>
</tbody>
</table>

AD and C are the patients and controls in the cross-sectional study of AD. The significance of differences between cognitive state (MMSE, ADAS-cog) values of the groups was calculated by an unpaired t test for C versus AD.

*Boldface indicates statistical significance at p < 0.001.

AD = Alzheimer disease; ADAS-cog = AD Assessment Scale–Cognitive Subscale; F = female; M = male; MMSE = Mini-Mental State Examination; SEM = standard error of the mean.
Association criteria and had a Clinical Dementia Rating global score of 1.0 at the time of the second blood collection.22

The protocol and procedures of this study received prior approval by the institutional review boards of the University of California, San Francisco, UKY, and the NIA Intramural Program. Informed consent was obtained from each subject.

Blood and CSF Sampling of Patients and Control Participants
Ten milliliters of venous blood were drawn by syringe into 0.5ml of saline with EDTA, incubated for 10 minutes at room temperature, and centrifuged for 15 minutes at 2,500 × g. Plasma samples were stored in 0.25ml aliquots at −80°C. CSF levels of P-T181-tau and Aβ 1–42 were quantified by xMAP Technology (Luminex Corporation, Austin, TX) using Inno-Bia AlzBio3 kits (Innogenetics, Ghent, Belgium).

Enrichment of Plasma ADEs for Extraction and Enzyme-Linked Immunosorbent Assay Quantification of Proteins
Aliquots of 0.25ml plasma were incubated with 0.1ml thromboplastin D (Thermo Fisher Scientific, Waltham, MA), followed by addition of 0.15ml of calcium- and magnesium-free Dulbecco balanced salt solution (DBS−2) with protease inhibitor cocktail (Roche, Indianapolis, IN) and phosphatase inhibitor cocktail (Thermo Fisher Scientific; DBS−3).17 After centrifugation at 3,000 × g for 30 minutes at 4°C, total exosomes were harvested from resultant supernatants by precipitation with 126μl per tube of ExoQuick (System Biosciences, Mountain View, CA) and centrifugation at 1,500 × g for 30 minutes at 4°C. To enrich ADEs, total exosomes were resuspended in 0.35ml of DBS−2 and incubated for 60 minutes at room temperature with 1.5μg of mouse antihuman glutamine aspartate transporter (ACSA-1) biotinylated antibody (Miltenyi Biotec, Auburn, CA) in 50μl of 3% bovine serum albumin (BSA; 1:3.33 dilution of Blocker BSA 10% solution in DBS−2; Thermo Fisher Scientific) per tube with mixing, followed by addition of 10μl of streptavidin-agarose UltraLink resin (Thermo Fisher Scientific) in 40μl of 3% BSA and incubation for 30 minutes at room temperature with mixing. After centrifugation at 800 × g for 10 minutes at 4°C and removal of the supernatant, each pellet was suspended in 100μl of cold 0.05M glycine-HCl (pH = 3.0) by gentle mixing for 10 seconds and centrifuged at 4,000 × g for 10 minutes, all at 4°C. Supernatants then were transferred to clean tubes containing 25μl of 10% BSA and 10μl of 1M Tris-HCl (pH = 8.0) and mixed before addition of 365μl of mammalian protein extraction reagent (M-PER, Thermo Fisher Scientific). Resultant 0.5ml lysates of ADEs were stored at −80°C. NDEs were prepared as described.23

ADE and NDE proteins were quantified by enzyme-linked immunosorbent assay (ELISA) kits for human tetraspanning exosome marker CD81, complement fragment C4b, decay-accelerating factor (DAF; CD55; ARP American Research Products, Waltham, MA; Cusabio Technology, College Park, MD), glutamine synthetase, complement receptor type 1 (CR1), factor I (ARP American Research Products; CloudClone Corp, Katy, TX), GFAP (EMD Millipore, Billerica, MA), complement fragment C3d, complement factor B, C1q portion of the C1 complement complex (Abcam, Cambridge, MA), Bb fragment of complement factor B (Quidel-Microvue, San Diego, CA), terminal complement complex fragment C5b-C9 (Elabscience, Bethesda, MD), CD59, interleukin (IL)-1β, mannose-binding lectin (MBL; Ray Biotech, Norcross, GA), tumor necrosis factor-α (TNF-α), complement factor D, and IL-6 (Thermo Fisher Scientific–Invitrogen, LaFayette, CO). The mean value for all determinations of CD81 in each assay group was set at 1.00, and relative values of CD81 for each sample were used to normalize their recovery.

Statistical Analyses
The Shapiro–Wilks test showed that data in all sets were distributed normally. Statistical significance of differences between means for cross-sectional groups AD and C (normal controls), and between longitudinal groups AD1 and C was determined with an unpaired Student t test, including a Bonferroni correction, and the significance of differences between means for
longitudinal groups AD1 and AD2 was determined with a paired Student t test (Prism 6; GraphPad Software, La Jolla, CA).

Results

Patients at the AD2 stage in the longitudinal study were older and had greater mean cognitive impairment at a level of mild to moderate dementia than the AD patients in the cross-sectional study with MCI or mild dementia (Tables 1 and 2). There was no significant difference in cognitive abilities between the control group and those at the A1 preclinical stage of AD in the longitudinal study.

For the cross-sectional study, mean CD81-normalized ADE levels of IL-6, TNF-α, and IL-1β all were significantly higher for AD patients than age- and gender-matched controls, but there was extensive overlap between the sets of values for AD patients and controls (Fig 1). To contrast quantities of the cytokine protein cargoes of ADEs with those of NDEs, NDEs were harvested immunochemically from the same precipitated populations of total plasma exosomes as the ADEs for 10 of the AD patients and their matched controls. CD81-normalized NDE values of TNF-α were 20.8 ± 2.15 pg/ml (mean ± standard error of the mean [SEM]) for AD patients and 26.3 ± 2.47 pg/ml for controls, respectively, which were significantly lower than those of ADEs (p < 0.001). Cytokine protein levels of IL-6 and IL-1β were not reliably detected in any of the NDE samples.

ADE levels of components, fragments, and complexes of the complement systems all were substantially higher than those of the immune cytokines assessed (Fig 2). CD81-normalized mean ADE levels of components exclusively of the classical pathway of complement, C1q and C4b, and exclusively of the alternative pathway of complement, factor B, factor D, and Bb were significantly higher for AD patients than controls (p < 0.0001). CD81-normalized mean ADE values of the complement fragments C3b and C3d, and of the C5b-C9 terminal complement complex (TCC) generated by both pathways also were significantly higher for AD patients than controls (p < 0.0001). Perhaps more importantly, there was far less overlap between values of the AD patients and controls for the complement effector protein analytes than the cytokines. In contrast, levels of MBL of the lectin-activated complement pathway in ADEs from AD patients and controls were indistinguishable and far lower than normal MBL concentrations in plasma of >7,800 pg/ml.24 As for cytokines, NDEs had substantially lower CD81-normalized levels of complement effector components than ADEs (Table 3).

In cross-sectional studies, CD81-normalized mean ADE levels of 4 membrane-associated complement regulatory proteins, but not fluid-phase regulatory protein factor I, were significantly lower for AD patients than controls (p < 0.01 for CR1, p = 0.0003 for CD46, and p < 0.0001 for CD59 and DAF; Fig 3). Attempts to quantify factor H with 2 ELISA kits based on different antibody pairs and ranges of sensitivity (Abcam 137975 and Ray Biotech ELH-CFH-1) yielded >3-fold disparate values, presumably attributable to differential recognition of factor H-like and other cross-reactive proteins.

In longitudinal studies, mean ADE levels of all complement effector proteins quantified were significantly higher at the AD2 stage of mild to moderate dementia than at the AD1 preclinical stage and for controls (Fig 4). However, there were no differences between the mean ADE levels of any complement effector protein assessed at the AD1 preclinical stage and those of matched controls. In contrast, for CD59 and DAF, the 2 complement
regulatory proteins with the greatest difference in levels between AD patients and controls in the cross-sectional studies, mean ADE levels were significantly lower at the AD1 preclinical stage than for controls. Progressive decline in ADE levels of CD59 and DAF with cognitive loss resulted in significantly lower levels of both complement regulatory proteins at the AD2 stage of moderate dementia than at the AD1 preclinical stage.

Control, AD1, and AD2 patient values (mean ± SEM), respectively, were 29.4 ± 4.20, 24.0 ± 3.32, and 71.8 ± 6.21 pg/ml for IL-6, 141 ± 10.3, 131 ± 7.46, and 221 ± 10.3 pg/ml for TNF-α, and 28.1 ± 2.91, 18.5 ± 2.07, and 54.0 ± 5.75 pg/ml for IL-1β. Thus, as for complement effector proteins, there were no differences between ADE levels of inflammatory cytokines at the AD1 preclinical stage and those of matched controls, but the levels at the AD2 stage were significantly higher than at the AD1 stage (p < 0.001).

Discussion
The capacity to enrich NDEs and ADEs separately from the same plasma samples has allowed analyses of a wide

![Image of Figure 2: Astrocyte-derived exosome levels of complement effector proteins in cross-sectional control and Alzheimer disease (AD) groups. Each point represents the value for a control subject or AD patient, and the horizontal line in point clusters is the mean level for that group. Mean ± standard error of the mean control and AD patient values, respectively, are 13,902 ± 1,105 pg/ml and 48,906 ± 2,528 for C1q, 64,305 ± 4,408 pg/ml and 166,151 ± 7,647 pg/ml for C4b, 48,705 ± 6,966 pg/ml and 416,093 ± 44,866 pg/ml for C3d, 113,321 ± 14,402 pg/ml and 547,292 ± 66,082 pg/ml for complement factor B, 1,465 ± 140 pg/ml and 5,800 ± 658 pg/ml for complement factor D, 1,465 ± 140 pg/ml and 5,800 ± 658 pg/ml for C5b-C9 terminal complement complex (TCC), and 874 ± 82.1 pg/ml and 1,141 ± 128 pg/ml for mannose-binding lectin (MBL). The significance of differences between values for controls and AD patients was calculated by an unpaired Student t test: **p < 0.0001. For comparison, neuron-derived exosome values were 68.8 ± 7.09 pg/ml, 11,562 ± 987 pg/ml, 9,354 ± 602 pg/ml, 14,624 ± 835 pg/ml, 7,128 ± 840 pg/ml, and 306 ± 29.1 pg/ml for C5b-C9 TCC, C3d, C4b, Bb, factor B, and factor D, respectively, in AD patients and were 54.2 ± 6.37 pg/ml, 1,855 ± 134 pg/ml, 3,851 ± 276 pg/ml, 6,029 ± 438 pg/ml, 2,055 ± 276 pg/ml, and 94.2 ± 10.7 pg/ml for C5b-C9 TCC, C3d, C4b, Bb, and factors B and D, respectively, in controls (Table 3).]
range of neural cargo proteins that are relevant to the pathogenesis of AD and other neurodegenerative diseases. Differences in levels of NDE proteins, which have primary and amplifying pathogenic roles, have proven to be practically useful for preclinical prediction of risk of development of AD and conversion from MCI to dementia. Abnormal levels of some NDE proteins correlate with the severity of dementia in AD, as determined by significant relationships with decreases in cognitive function and with losses of brain mass in magnetic resonance imaging studies. Levels of some proteins involved in the generation of neurotoxic amyloid peptides are higher in ADEs than NDEs, suggesting that transfer of these enzymes in ADEs to neurons may represent one mechanism for neurotoxic effects of reactive astrocytes. Measuring the levels and activities of amyloid peptide-generating enzymes in ADEs before and after treatment may provide a test method for assessing in vivo effects of drugs directed to these pathways.

New findings described here of elevated ADE levels of classical and alternative complement pathway proteins in AD patients compared to those of matched control subjects suggest that type A1 reactive astrocytes may generate these inflammatory mediators and deliver them to other

### TABLE 3. Differences in Levels of Complement Components in ADEs and NDEs

<table>
<thead>
<tr>
<th></th>
<th>C5b-9 TCC</th>
<th>C3d</th>
<th>C4b</th>
<th>Bb</th>
<th>Factor B</th>
<th>Factor D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cntrl</td>
<td>AD</td>
<td>Cntrl</td>
<td>AD</td>
<td>Cntrl</td>
<td>AD</td>
<td>Cntrl</td>
</tr>
<tr>
<td>ADEs</td>
<td>355</td>
<td>1,212</td>
<td>48,705</td>
<td>416,093</td>
<td>64,305</td>
<td>166,151</td>
</tr>
<tr>
<td>NDEs</td>
<td>54.2</td>
<td>68.8</td>
<td>1,855</td>
<td>11,562</td>
<td>3,851</td>
<td>9,354</td>
</tr>
</tbody>
</table>

All values shown are mean pg/ml (values for mean ± standard error of the mean are in the text of Results or in the legend for Fig 2). All differences between levels of corresponding analytes in ADEs and NDEs are significant at \( p < 0.0001 \).

*AD = Alzheimer disease patients; ADE = astrocyte-derived exosome; Cntrl = controls; NDE = neuron-derived exosome.

---

***FIGURE 3: Astrocyte-derived exosome levels of complement regulatory proteins in cross-sectional control and Alzheimer disease (AD) groups. Each point represents the value for a control subject or AD patient, and the horizontal line in point clusters is the mean level for that group. Mean ± standard error of the mean control and AD patient values, respectively, are 1,211 ± 68.5 pg/ml and 398 ± 37.1 pg/ml for CD59, 57.2 ± 4.39 pg/ml and 36.1 ± 2.47 pg/ml for CD46, 447 ± 31.4 pg/ml and 336 ± 26.1 pg/ml for CR1, 35,197 ± 3,735 pg/ml and 4,563 ± 654 pg/ml for decay-accelerating factor (DAF), and 6,281 ± 562 pg/ml and 5,010 ± 346 pg/ml for factor I. The significance of differences between values for controls and AD patients was calculated by an unpaired Student t test: *\( p < 0.01 \), **\( p < 0.0001 \).***
CNS cells by ADEs (see Fig 2). Elevated concentrations of C4b and Bb in ADEs of AD patients support involvement of both the classical and alternative complement pathways in the generation of C3b and C5b-C9 TCC. The low levels of MBL without a difference between ADEs of AD patients and controls is against involvement of the lectin complement pathway. Delivery of C3b to neurons by ADEs and its display on neuronal surface membranes may initiate microglial cytotoxic attacks on the affected neurons. C3b on neuronal surface membranes also may evoke local generation of C5b-C9 TCC in addition to the preformed C5b-C9 TCC delivered by ADEs, both of which complexes would be capable of damaging neurons. These neurotoxic complement fragments and complexes may be delivered largely by ADEs through their established mechanism of direct intercellular communication. Enhanced activity of C3 convertases of the classical and alternative complement systems, greater generation of C5b, and increased assembly of C5b-C9 TCC all would be amplified by the acquired deficiencies of multiple complement regulatory proteins, especially CD59 and DAF (see Fig 3). Levels of the plasma-based factor I, which with cofactor H or CD46 constitutes a C3b/C4b inactivator, were no different in AD patients than controls. Neuronal damage by the complement pathways also could be mediated by C3a and C5a, the inflammatory anaphylatoxins generated concurrently with larger fragments, although these have not been examined in the present study.29

FIGURE 4: Astrocyte-derived exosome levels of complement proteins in the longitudinal study. Each point represents the value for a control subject or Alzheimer disease (AD) patient, and the horizontal line in point clusters is the mean level for that group. Control, AD1 patient, and AD2 patient values (mean ± standard error of the mean), respectively, are 63,621 ± 3,056, 63,901 ± 3,130, and 163,273 ± 4,864 for C4b, 62,958 ± 8,945, 86,911 ± 10,020, and 215,660 ± 23,018pg/ml for C3d, 82,681 ± 3,921, 84,385 ± 12,808, and 548,930 ± 77,855pg/ml for complement factor B, 85,716 ± 6,181, 85,123 ± 4,836, and 247,574 ± 10,740pg/ml for factor B fragment Bb, 24,347 ± 2,350, 22,212 ± 1,866, and 70,039 ± 5,245pg/ml for C3b, 400 ± 43.4, 359 ± 31.7, and 832 ± 87.2pg/ml for C5b-C9 terminal complement complex (TCC); 1,272 ± 61.4, 757 ± 33.6, and 409 ± 15.4pg/ml for CD59, and 32,123 ± 1,733, 13,352 ± 803, and 4,369 ± 320pg/ml for decay-accelerating factor (DAF). The significance of differences between values for controls and AD1 patients was calculated by an unpaired Student t test, and the significance of differences between values for AD1 and AD2 patients was calculated by a paired Student t test: *p < 0.01, **p < 0.0001.
Diminished ADE levels of membrane-associated complement regulatory proteins CD59 and DAF in AD relative to those in control subjects were found at the preclinical AD1 stage of AD, when complement effector proteins were still at control levels (see Fig 4). This time course for development of complement abnormalities suggests that inadequate control is the primary underlying mechanism of enhanced complement activation in reactive astrocytes. An immunohistochemical study of postmortem human brain tissues in AD had shown staining for C3 and C4 fragments, C1q, and C5b-C9, with intensities that paralleled amyloid plaque density.30 In the same brain tissues, the complement regulatory proteins CD59, CR1, DAF, and MCP (CD46) were not detected, raising the possibility of lack of control of activation of complement pathways. CR1 antigens were detected in astrocytes in culture and in brain tissues subsequently, but neither CR1 levels nor binding activity accounted for the associations of sporadic AD with some genetic variants of CR1.31 More complete analyses may be required, however, as results of genome-wide association studies of AD have implicated single nucleotide polymorphism variants of CR1 as possible risk factors.32,33

ADE cytokine and effector complement abnormalities are not present preclinically, but were manifested significantly at the time of onset of MCI or dementia (see Figs 1 and 2, and 4). Abnormal levels of complement and cytokine proteins show the greatest abnormalities in later stages of the disease in this small number of study subjects (see Fig 4). ADE levels of TNF-α and IL-1β in AD are similar to those generated by microglia, which initiate transformation of astrocytes into the neurotoxic reactive A1 type. Thus, these low levels of cytokines in ADEs may be most important for promoting continued production of neurotoxic type A1 astrocytes in AD lesions rather than mediating neuronal damage directly.

Many types of future investigations of the astrocyte sources and cytotoxic mechanisms of complement proteins in ADEs will be required to validate our initial findings. If distinctive membrane protein markers of the A1 and A2 subtypes of astrocytes are identified, it will be important to resolve these subtypes and investigate their respective capacities to generate complement proteins and to evaluate the separate neurotoxic potential of ADEs from A1 and A2 astrocytes. Furthermore, larger numbers of subjects will be needed to delineate the relative roles of the classical and alternative complement pathways in AD, better define the time course of involvement of each ADE cargo protein mechanism, and improve our understanding of potential roles of these measurements as late-phase biomarkers in AD and other neurodegenerative diseases. It is of special interest that both complement pathways and their neurotoxic products are present at potentially functional levels in ADEs of cognitively normal elderly subjects. Complement mediators thus may be one mechanism for induction of neuroinflammation in normal aging, but such conclusions will require at the least studies with younger control groups.

If our findings are validated, they may inform possible future therapies. The administration or enhanced local generation of one or more recombinant complement control proteins early in AD, guided by their diminished levels in plasma ADEs of individual patients, could limit recruitment of complement mechanisms preventatively. In later phases of AD, when complement activation has appeared, neutralizing monoclonal antibodies to effector complement components or their receptors, decoy complement receptors or receptor antagonists, and esterase inhibitors of complement mediator generation may suppress ongoing complement-mediated neuronal injury.

Acknowledgment
This work was supported by a grant from the Biomarkers across Neurodegenerative Diseases 2 program of the Michael J. Fox Foundation for Parkinson’s Research, the Alzheimer’s Association, Alzheimer’s Research United Kingdom, and the Weston Brain Institute (E.J.G.); and by the NIH National Institute on Aging (NIA; P30028383; G.A.J.). D.K. was supported by the Intramural Research Program of the NIH NIA.

We thank Drs J. Atkinson and K. F. Austen for their advice about studying complement, and J. H. Goetzl for expert preparation of the illustrations.

Author Contributions
E.J.G. and D.K. contributed to the conception and design of the study; all authors contributed to the acquisition and analysis of data; E.J.G., D.K., E.L.A., and J.B.S. contributed to drafting the text.

Potential Conflicts of Interest
E.J.G. has filed an application with the U.S. Patent Office for the platform and methodologies described in this report.

References